The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
APPLIED GENETIC TECHNOL CORP COM 03820J100 5,751 1,455,904 SH   SOLE   1,455,904 0 0
CIDARA THERAPEUTICS INC COM 171757107 10,990 1,356,813 SH   SOLE   1,356,813 0 0
EIGER BIOPHARMACEUTICALS INC COM 28249U105 17,596 1,599,592 SH   SOLE   1,599,592 0 0
GLAUKOS CORP COM 377322102 33,606 1,018,362 SH   SOLE   1,018,362 0 0
INVUITY INC COM 46187J205 9,614 1,080,272 SH   SOLE   1,080,272 0 0
KALVISTA PHARMACEUTICALS INC COM 483497103 2,221 329,942 SH   SOLE   329,942 0 0
MACROGENICS INC COM 556099109 19,854 1,074,316 SH   SOLE   1,074,316 0 0
OBALON THERAPEUTICS INC COM 67424L100 23,380 2,453,338 SH   SOLE   2,453,338 0 0
TESARO INC COM 881569107 261,007 2,021,738 SH   SOLE   2,021,738 0 0
XENON PHARMACEUTICALS INC COM 98420N105 24 8,293 SH   SOLE   8,293 0 0